Induction of Clinical Response Using Rifaximin in Crohn's Disease
Status:
Completed
Trial end date:
2020-11-03
Target enrollment:
Participant gender:
Summary
Antibiotics have been used to treat Crohn's disease symptoms with the best studied
antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is
FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is
very poorly absorbed and over 97% of the drug taken orally is excreted in the feces.
The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for
the treatment of moderate to severe symptoms of Crohn's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Scott Lee
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.